Belite Bio, Inc (BLTE)

Market Cap	1.96B
Revenue (ttm)	n/a
Net Income (ttm)	-42.55M
Shares Out	32.54M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,521
Open	59.03
Previous Close	58.63
Day's Range	59.00 - 61.04
52-Week Range	43.70 - 86.53
Beta	-1.51
Analysts	Strong Buy
Price Target	96.67 (+60.18%)
Earnings Date	Aug 8, 2025

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: BLTE
• Website: https://www.belitebio.com

Analyst Summary

According to 4 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $96.67, which is an increase of 60.18% from the latest price.

Price Target

$96.67

(60.18% upside)

Analyst Consensus: Strong Buy